Charles Coombes

Imperial College London

Professor Coombes is Professor of Medical Oncology at Imperial College London and runs the Imperial Translational Breast Cancer Group. He is also Chairman of the International Collaborative Breast Cancer Group. A world-leading breast cancer expert, his research interests include novel methods for prediction of response to endocrine therapy in breast cancer and carrying out research aimed at understanding the mechanisms of resistance to endocrine therapy and development of novel anti-cancer drugs.

William J. Gradishar

Northwestern University

Dr Gradishar is Betsy Bramsen Professor of Breast Oncology in the Division of Hematology and Medical Oncology at the Feinberg School Medicine at Northwestern University and a member of the Robert H. Lurie Comprehensive Cancer Center. He is Director of the Maggie Daley Center for Women's Cancer Care.

His clinical research interest focuses on the development of novel therapies for the treatment of breast cancer using precision medicine to define the right therapy, for the right patient at the right time.

Rinath Jeselsohn

Dana-Farber Cancer Institute

Dr Jeselsohn is Assistant Professor, Medicine, Harvard Medical School, Associate Physician, Medicine, Brigham and Women's Hospital and Assistant Professor, Medical Oncology, Dana-Farber Cancer Institute.

A physician-scientist active in translational research studying mechanisms of endocrine resistance and strategies to improve treatment for hormone receptor positive breast cancers. She is also engaged in the care of breast cancer patients and innovative clinical trials with the goal to identify new treatments to improve outcomes in breast cancer patients.

Patricia LoRusso

Yale School of Medicine

Professor Lo Russo is Director of the Early Phase Clinical Trials Program and Associate Center Director of Experimental Therapeutics at Yale Cancer Center, Yale University.  Dr. LoRusso has over 30 years of expertise in medical oncology, drug development, and early phase clinical trials. Prior to her Yale appointment, Pat served in numerous leadership roles at Wayne State University’s Barbara Karmanos Cancer Institute, most recently as director of the Phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.

Joyce O’Shaughnessy

Texas Oncology-Baylor Charles A. Sammons Cancer Center

Joyce A. O’Shaughnessy, M.D. specializes in medical oncology with board certification in both internal medicine as well as medical oncology. She is a Diplomate of the American Board of Internal Medicine with subspecialty certification in medical oncology. Dr. O’Shaughnessy focuses on her practice and clinical research on breast cancer treatment. She is Director of Breast Cancer Research and at Baylor-Sammons Cancer Center and Chair of Breast Cancer Research for US Oncology.  Her Research Interests include Genotype-Phenotype correlations for high-risk breast cancers and immunotherapy for triple negative breast cancer.

John Robertson

University of Nottingham

Professor of Surgery in the Faculty of Medicine and Health Sciences, and Director of the Centre of Excellence for Autoimmunity in Cancer, Professor Robertson leads the team looking to develop the world’s first blood test for the early detection of breast cancer. An internationally recognized expert in breast cancer he played a pivotal role in the development of the Selective Estrogen Receptor Degrader (SERD) fulvestrant. He is also involved in a number of studies in the development of oral SERDs.

Adam Schayowitz

Pfizer, Vice President, Development Head, Breast Cancer, Colorectal Cancer and Melanoma

Adam Schayowitz, PhD, MBA is the Development Head for Breast Cancer, Colorectal Cancer and Melanoma at Pfizer Oncology. He joined Pfizer in 2018 to lead the prostate cancer franchise, grounded in XTANDI. He then became responsible for the Precision Medicine Franchise (Colorectal and Melanoma) based on the Array acquisition and in 2021 added the breast cancer portfolio to his responsibilities. Adam’s primary responsibility is to lead the teams responsible for the development and lifecycle management of Ibrance, ARV-471 and the late stage breast cancer pipeline. Prior to joining Pfizer, Adam lead the development of Zejula (niraparib) at Tesaro, including the pivotal phase 3 ovarian cancer program as well as other global studies in breast cancer, lung cancer, and prostate cancer in collaboration with Janssen. Based out of Cambridge, MA, Adam holds a PhD in pharmacology from the University of Maryland and an MBA from Johns Hopkins.